-

Ollin Biosciences to Participate in Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences:

2026 Jefferies Global Healthcare Conference
1x1 Meetings: Tuesday, June 2
New York, NY

Evercore 2026 Emerging Private Biotech Conference
Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET
Newport, RI

About Ollin Biosciences

Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

Contacts

Media:
Katie Engleman
1AB
katie@1abmedia.com

Industry:

Ollin Biosciences, Inc.

Release Versions
English

Contacts

Media:
Katie Engleman
1AB
katie@1abmedia.com

More News From Ollin Biosciences, Inc.

Ollin Biosciences to Participate in Two Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences. Piper Sandler Biopharma Symposium 1x1 Meetings: Wednesday, April 15, 2026 Location: Boston, MA UBS Private Biotech Summit 1x1 Meetings: Monday, May 18, 2026 Location: New York, NY About Ollin Biosciences Established...

Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced final 20-week study completion data from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324, a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration...

Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324, a next-generation VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in over 160 patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). OLN324’s up to 60-fold high...
Back to Newsroom